Question-and-Answer Session
Operator
Thank you. [Operator Instructions] We have a initial doubt from Michael Leuchten, Barclays. Please go ahead.
Michael Leuchten
Thank you. It’s Michael Leuchten from Barclays. Two doubt for me, please. One for Olivier. The Capital Markets Day in a second half is sourroundings yourself utterly an desirous calendar to promulgate your perspective of a company’s devise and positioning going forward. But one of a hurdles we consider in a new past has been burden within a organization. So, I’m usually wondering, are we meditative around a timing and afterwards secondly how are we meditative will it be addressing a softer factors as against to a tough monitoring of launches and maybe RD productivity?
And afterwards a second doubt for Jérôme. we interpretation your criticism around a handling expenses, still design to grow 5% in a full year though it did grow reduction than that in a initial entertain and if we consider about a timing of a additional launches entrance by where accurately do we design that acceleration to flog in on a handling responsibility side, please? Thank you.
Olivier Brandicourt
Michael, unfortunately, it was not clear. We couldn’t listen unequivocally good or hear unequivocally well, sorry. we know a Capital Market Day. As we pronounced in my remarks, we consider we are going to do that in a second half. we unequivocally need to go by low business reviews. As we said, we’ve launched this vital formulation examination also in parallel. We consider we competence have those formula someday during a second half, many substantially during a third entertain — fourth quarter, contemptible and we will give we a accurate date during a call for a second quarter. And a doubt on comps, unequivocally I’m not certain we accepted what we customarily pronounced in this organization, burden has not been customarily unequivocally clear. Well, let me tell we one thing. If that is a box and I’ve not seen that yet, I’ll make certain that it doesn’t final too long.
Jérôme Contamine
Yeah. Michael, so on OpEx as we noticed, we mean, a OpEx in a initial entertain augmenting by 3.7%. we continue to beam around 5% boost in a mid-single digits, so not ask me to be too accurate though let’s contend around 5% OpEx boost for a all year. So here, we meant dual things. we meant OpEx, RD and SGA. So on RD clearly, we don’t consider a settlement of decreased net RD expenses, that we saw in a initial entertain will be solid in a subsequent quarter.
Clearly, we have a vast clinical hearing module and we design to see that augmenting rather on a call this year what we gave as a full year superintendence when we had a call in February. When it comes to SGA, we won’t go into too most fact though maybe we should remember a few things. First of all, we have now entirely hedged sales and selling classification for Lemtrada, that has a possess sales force.
And this happened to took place in a second half, this time fundamentally in a fourth quarter. So, on a like-for-like basis, it will continue to impact a OpEx expansion in Genzyme between quarter-to-quarter. Second, clearly we are going to deposit some-more over a credentials of a launch of Praluent, as we go and even some-more if we launch it, we clearly design to get that and take place in second half of a year.
And afterwards as we know, we mean, there is also some seasonality in a OpEx and possibly we take vaccine or we take Merial. It’s not usually a unchanging evolution. So altogether, we meant there is zero unequivocally new here. We need to deposit in nutritious a launches of these unequivocally sparkling products and also there are some automatic effects, that are usually ensuing from investments we did on a full year impact we will have in a entrance quarters.
Sébastien Martel
Thank you, Jérôme. Next question, please?
Operator
Thank you. The subsequent doubt is from Vincent Meunier, Morgan Stanley. Please go ahead.
Vincent Meunier
Hello. Thank we for holding my questions. So a initial one is on a U.S. diabetes trend. So, we know that a 15% cost decrease in initial entertain will sojourn during matching spin in a remaining of a year, so can we elaborate on a impact for Toujeo? we mean, what is for instance, a net cost of Toujeo contra Lantus now and how it is approaching to develop in a subsequent quarters?
And a second doubt is on Genzyme, that is an vicious motorist for we not usually for a topline though also a bottom line. Can we greatfully give some-more sum on a profitability of Genzyme? And should we design a new product launches to tip serve improvements of a profitability of Genzyme?
Olivier Brandicourt
All right. Thank you, Vincent. So, we consider a initial doubt is for Peter. Peter, if we are prepared to answer a doubt on Toujeo? And afterwards David, we will take doubt on Genzyme.
Peter Guenter
Yeah. Vincent, so interjection for a question. A integrate of points on Lantus Toujeo. So first, we have some unequivocally enlivening signs. It is now given 5 uninterrupted months, a altogether marketplace share over within a fundamental insulin marketplace has stabilized during a spin of 69% if we demeanour during a Rxs. As already mentioned by Olivier in a introduction, we are creation intensely good and discerning swell with marketplace entrance and indeed over a expectations. And that is indeed due to a refinement, a new excellence of a constrictive devise on a altogether glargine franchise.
You will know that we will not give we any sum between a opposite elements of this brew for rival reasons. The pivotal indicate unequivocally here is that on tip of a stabilization of a Lantus marketplace share, that apparently is a fast bottom now for a Toujeo launch and we have 70% of blurb lives lonesome though restrictions and already tighten to 50% of a Part D population, that is unequivocally according to a believe an intensely fast entrance of a market.
And another point, we would like we to discuss is that we have reissued a long-term superintendence on diabetes that is prosaic to somewhat growing, so there is no change in a long-term superintendence on diabetes. And we continue to be positively assured that these rates of Lantus to Toujeo will kick a consensus, that is now as we substantially know during 20%.
Now in terms of initial feedback on Toujeo launch, apparently it’s unequivocally early days. We have launched a product given reduction than a month. What we can tell we is that a initial feedback from a business is unequivocally good, that is honestly took us another warn that we have a permanent in tide in a U.S. marketplace of $1 million patients on a yearly basement of new to be insulin eye inspections and these are apparent possibilities for Toujeo.
And afterwards a subsequent pool of patients is of course, those patients who are now not optimally treated with a existent fundamental insulin, possibly that is Lantus or any other fundamental insulin. Either for reasons of deficient HbA1c control, possibly for reasons of high poise or a multiple of both finish and honestly it is of march obviously, mostly a multiple of both.
And so on pricing, a usually thing we can tell we on tip of that is that a WACC price, so a indiscriminate of merger cost is between Lantus and Toujeo is matching on a unit, per section price. But of course, we will not give we anymore fact on that pricing.
Sébastien Martel
All right. Thank you, Peter. David, are we prepared to answer a doubt on Genzyme?
David Meeker
Yes. So a Genzyme within Sanofi, we don’t rash a full finish PL. So we can’t give we accurate profitability for Genzyme. Early RD is carried on a corporate page and common services also are carried on a corporate page. So like we said, a accurate numbers are forthcoming. What we can tell we is that a singular illness business is even when we do severe calculations, dynamically essential and that profitability is utterly a fast conditions and pricing as remained comparatively stable.
The other lines on a PL have a certain spin of stability. So, we consider that should continue to a bit essential and dynamically essential and we continue expansion on this good prospects for a singular illness business. The MS business, I’m rising dual of these, both of these products in a past 18 months. And apparently there is a poignant investment that goes along with that.
We did spin essential final year. Even acknowledging, we don’t have full discernment if we will into all aspects that competence strike that PL. But a MS authorization we think, Jérôme highlighted and we’re on lane and sincerely high expansion settlement here. And we consider a profitability from this indicate brazen should grow utterly significantly for a MS business as well. So absent numbers and those are a trends.
Sébastien Martel
All right. Thank we unequivocally much, David. Next doubt please.
Operator
Thank you. The subsequent doubt is from Steve Scala, Cowen. Please go ahead.
Steve Scala
Thank you. A integrate on Toujeo, can we elaborate on a polished constrictive devise in a U.S.? And given a excellence was compulsory and what is a excellence relations to? So for instance, is it excellence contra a devise we had a year ago or is it a some-more new shift? And associated to that a before superintendence for Toujeo was good some-more than 20% of a glargine authorization in 3 years. So formed on this polished constrictive strategy, are we prepared to labour that theory and maybe competence get good some-more than 50% in 3 years? Thanks.
Sébastien Martel
Thank you, Steve. So that’s again for you, Peter.
Peter Guenter
Yeah. Steve, so interjection for a question. The constrictive devise is indeed a new excellence of a constrictive strategy. And as we mentioned before, a vital aim is unequivocally to speed adult a marketplace additional for Toujeo given we are entirely committed and entirely assured to a long-term intensity of this product and of course, a vital significance of not usually carrying new patients though also acid patients from a existent Lantus to a new Toujeo.
In terms of where we should land, this is a unequivocally formidable question. We are now not prepared to give we any accurate number. But we sojourn committed what we pronounced during a New Medicines Day that is to say, we are assured that we will have switch rates and good above a accord that is out there now that is 20%. And we remind we also that a entrance that we have already got it so distant is though restrictions, that is of march also facilitating significantly a medication by a physician.
Steve Scala
Thank you.
Sébastien Martel
All right. Thank you, Steve. Next question, please?
Operator
Thank you. The subsequent doubt is from Jo Walton, Credit Suisse. Please go ahead.
Jo Walton
Thank you. we consternation if we could tell us a small bit about how Lantus is doing in Western Europe where you’ve had unequivocally clever expansion for a past few quarters. Is this tolerable during a tide level? And on Praluent, in a core box that we identified in Mar — we identified it as Mar 2016 as of expedited date. Does that meant that a justice isn’t going to meddle during anytime before than given we would’ve approaching both products to have been authorized good before Mar 2016?
Operator
Mr. David Meeker, can we greatfully respond to a question? I’m reconnecting a other speaker. Thank you.
David Meeker
As a usually one on — again, we consider we should wait until they join behind given that’s on a diabetes Praluent business, so let’s give it a minute.
Operator
Ladies and gentlemen, appreciate we for holding we are reconnecting one of a speaker. Thank you. Would we like me to take another doubt sir?
Elias Zerhouni
Are we means to reconnect or…
Operator
We are still perplexing to hit a other speaker, we can take another question, if we would like?
Elias Zerhouni
So apparently we can pronounce to Genzyme issues, though we consider we should really try to reconnect here, we need to…
Anny Kykiaki
We are on a apart line here Elias.
Operator
We now are incompetent to join a speaker. Would we like to — would we like us to give a building to another question?
Jo Walton
Should we try a doubt on Genzyme would that be better?
Elias Zerhouni
Yeah. We can positively do that again, we think, with 10 mins to go on a call here, we should demeanour to hang it up, though they are not means to be on, we think, a — it’s substantially not value perplexing to continue a full call.
Jo Walton
Well, if we can ask a doubt on Genzyme? we consternation if we could tell us a small bit some-more about a uptake of Cerdelga. You’ve apparently usually launched it. It’s been into a few countries. Can we tell us where it’s being used? Is it studious holidays? Just give us a small bit some-more of a clarity of how fast we could see that ramp up?
Elias Zerhouni
Sure. Yeah. we consider when we launched Cerdelga, a verbal therapy for Gaucher disease. The suggestion of that launch was that we combined a choice for patients and a information uncover that it was rarely allied to Cerezyme or enzyme deputy therapy. And so we design to going in that it would be a right choice for some patients not for others.
So now we are gratified with a launch. we think, what we would inspire we to demeanour during as we pronounced final time as a altogether Gaucher franchise, we are flourishing during over 10% during a tide rate globally.
In a U.S. we have over 200 patients on therapy and a series of patients were going by screening for to make certain that they have a right spin to be means to metabolize a drug that is also — we consider those numbers demeanour good. So, again, we competence concentration here as unequivocally most on a altogether authorization reduction on a Cerdelga uptakes specifically, though we am greatfully so distant with where we are.
Jo Walton
Thank you.
Operator
Thank you. We have another doubt from Florent Cespedes from Société Générale. Please go ahead.
Florent Cespedes
Good afternoon, gentlemen. Thank we for holding my questions. Two discerning ones, one for Olivier, one for Elias. First, for Olivier, in your prior company, we appreciated your useful proceed and your equivalent perspective on a group. What could we do during Sanofi to…
Anny Kykiaki
Excuse me, I’ve got him on a phone, Elias. Hello?
Elias Zerhouni
Hi sorry.
Anny Kykiaki
Excuse me, can we hear me?
Olivier Charmeil
Anny.
Anny Kykiaki
Yes.
Olivier Charmeil
You can we can hang up, we are — we have reconnected we had vital energy mangle here in a Paris HQ officer.
Anny Kykiaki
Okay. Thank you.
Olivier Charmeil
Reconnected into a call. Sorry, Florent we are going to have to repeat your question, Olivier.
Florent Cespedes
Okay. No problem. So for Florent Cespedes, Société Générale. Two discerning questions, a initial for Olivier. So as we said, in your prior company, we appreciated your useful proceed or your equivalent perspective on a group. Now, during Sanofi, what could we do to boost prominence on a group? Could we visualize maybe to give a kind of aspirational long-term superintendence after this year during a Investor Day or something some-more kind of accurate superintendence like during Bayer, could we have your thoughts on that?
My second question, for Elias. Could we have some-more sum on given we motionless to stop a opposite projects in RD in oncology, Crohn’s and ophthalmology? Is it due to a miss of differentiation, reserve or prioritization? Thank we unequivocally much.
Olivier Charmeil
Yeah. All right, Florent. So your question, again, we couldn’t hear we unequivocally well, though it’s on a LT superintendence latter this year. we meant to be honest it would be premature, right, for me to tell we that we am going to switch to guidance, it’s a same form of superintendence we have and we had Bayer for instance.
I have to go by what we described a business examination and vital formulation and come to a finish of how to best beam in destiny years. So it’s really something we have in mind, that’s positively there, though we need to give me some time. And so, RD, Elias.
Elias Zerhouni
Yes. So a doubt relates, if we listened it scrupulously about a decisions we done in oncology. Fundamentally, we endorse to concentration on a earnest programs a CD38 antibody module a or antibody dump conjugate programs we have and a c-MET kinase.
And as we mentioned, we — we predictably reviewed all a other programs with a results, and somewhere essentially consummated given of miss of differentiated efficacy, we suspicion in a couples for signals that we didn’t consider could be managed brazen given a tide environment. And a third reason is we are also operative on a unequivocally early portfolio immuno-oncology that we wish to make some room for it, that we’ll speak about later.
Florent Cespedes
Thank we unequivocally much.
Olivier Charmeil
Yes. So again a apologies, though as we usually pronounced before you, Florent, we had a energy cut and during a time we had a doubt from Jo Walton on Lantus, so maybe Peter, if we wish to take this one.
Peter Guenter
Yeah. So maybe, a partial of a doubt we still perceived before a energy cut was on a conditions of Lantus in Western Europe and we guess, also by prolongation your doubt was also pertained to a altogether Lantus, Toujeo.
So a integrate of points on Western Europe, so we are doing well, we are unequivocally gratified by a performance. There is really no cost boost in Europe rather a consistent cost erosion and we have again delivered some-more than 6% expansion from Lantus in a initial entertain and we are indeed unequivocally rival within a fundamental segments in almost all a countries in Western Europe.
And for what concerns Toujeo and a good news is that Toujeo will in Germany not have to go by a opposite procession and we have seen in a final integrate of years generally in a margin of diabetes some vital drawbacks of diabetes drugs going by a opposite procedure. So that is a unequivocally good news. And a small bit like in a U.S. by a way, we have done — we have been creation unequivocally clever swell on constrictive with a German [indiscernible] with a German funds.
So we are assured of carrying a good lift adult in Germany. Also that we got registration finish of final week, we have a unequivocally rival tag this time in Europe and so all this creates us flattering assured indeed on a European launch of Toujeo. And so that is a small bit a design we can paint to we in nutshell for Europe.
Olivier Charmeil
Thanks Peter. We are going to take subsequent doubt please?
Operator
Thank we unequivocally much. The subsequent doubt is from Graham Parry, Bank of America. Please go ahead.
Graham Parry
Great. Thanks for holding my questions. So, firstly, Olivier, you’ve summarized your priorities for a near-term and discussed a vital review? But could we give us a feel for a border of that vital review? So do we consider a range of a company, as it sits right now is about right? So is a examination about meditative around a edges or is there something potentially some-more cathartic than this about to happen?
And afterwards secondly, on Toujeo, could we usually give us a feel for primarily where patients are entrance from? Is this primarily new patients or switches from Lantus and on a access, how most of that is Tier 2 elite standing or maybe usually in a same or improved Tier than Lantus rather than usually being unlimited access? Thank you.
Olivier Charmeil
All right. Thank you, Graham. And given we are on Toujeo can we take a Toujeo doubt first?
Peter Guenter
Yeah. Hi, Graham. So as we already mentioned in terms of studious sourcing, so there are dual apparent segments, so a approximately 1 million new patients in a U.S. So this is for us a low unresolved organisation we are going after aggressively.
And also those patients that are not a thought experiencing high post-combination of both fear of hypos, and we have all programs in place indeed to make certain that we maximize a income tide of these dual segments.
Your questions on marketplace entrance Tier 2, Tier 3 is contingent from devise to plan, obviously, now there is a reduction of both. In blurb we substantially will have prisoner that we have a good bid in place with co-payment equivalent programs possibly this is a exemplary couponing module or with a some-more programmed co-pay equivalent module in a pharmacies, with Relay Health. So indeed a co-pay for a studious is unequivocally rival compared to what is out there for existent bottom of insulins. And afterwards in a Medicare Part D, actually, as it becomes open in a entrance days, we will see a lot of indeed tier dual coverage.
Jérôme Contamine
On a vital review, this is again going to be a subjects of a subsequent few months. But we wish to be transparent when we was referring to for a second half of a year will be business refurbish rather than a display on a strat skeleton for a altogether group. Now we have to say, that Board and I, we are already giveaway aligned around executing what Sanofi diversified business models is.
And we keep in mind that, while diversified, we wish to finish in a business where we can and we will win. So we’ll keep also an open mind per serve opportunities to optimize a companies’ portfolio while we are doing that consummate business examination and vital review. So that’s what we can share during this point. So appreciate you, Graham. Next doubt please.
Operator
Thank you. The subsequent doubt is from Tim Anderson with Sanford Bernstein. Please go ahead.
Tim Anderson
Hi. I’m devising that you’ll contend it’s too early to criticism on 2016 in terms of a opinion for a diabetes franchise, though investors are positively looking past 2015 during this indicate and into 2016, given a landscape gets some-more rival and we consider some-more capricious for Lantus and Toujeo with Lilly entrance to marketplace and with Novo substantially entrance to market. Wondering if we can during slightest endorse directionally how we design that franchise, your altogether diabetes franchise, to perform in 2016? Would it be protected to assume that it would approaching be reduce in 2016 altogether than what it would be in 2015?
And second doubt for we is on dupilumab. In a press recover and a slip deck, we speak about several arriving catalysts opposite a pipeline. we didn’t see on there a initial Phase III readout of dupilumab in atopic dermatitis. we suspicion that competence occur by year end, though can we give us updated timing for when investors competence learn about a initial — a readout of that initial Phase III trial?
Jérôme Contamine
Well, I’ll answer a initial — Tim, a initial doubt quickly. Our superintendence is fast between 2015 to 2018 for diabetes business is concerned. So it’s stable, usually somewhat increasing. So that has no possibility and to give we a some-more granular design for 2016 during this indicate would be unequivocally difficult. So a other doubt has to do is LixiLan or dupilumab? Dupilumab.
Olivier Brandicourt
Well, maybe, Peter, we wish it contend we’re about LixiLan and this is apparently partial of a year outlook
Tim Anderson
Year outlook.
Peter Guenter
Yeah. Tim so in a prolonged tenure outlook, there are as we mentioned yourself, a integrate of elements. There are rival elements. There are elements of a augmenting Sanofi portfolio in diabetes. Of march this cost vigour on a marketplace we have baked in all these elements in a long-term guidance. And for example, if we consider about a LixiLan now that we have ELIXA routine certain study, and we would have a readouts of a LixiLan studies in a third entertain of this year.
We will record LixiLan of march as theme to a certain readout of Phase III by a finish of this year, and LixiLan would therefore be a initial and usually repair those between fundamental insulin and a GLP-1 with proven cardiovascular reserve and for a insulin and for a GLP-1. You know also that aged products fit intensely good together. Lantus is operative on FPG, Lixi operative on PPG so this is a unequivocally synergetic combination. So we can lift thing, this is one of a item we have in a portfolio that is a small bit ignored by some of your, we contingency contend and we’re flattering vehement by this product. And so we consider I’ll spin it over to Elias for a doubt on dupilumab.
Elias Zerhouni
Yes. So, as we know we started Phase III in a fourth entertain ‘14, and a skeleton are to contention a focus for dupilumab in a fourth entertain of 16. Also, we should know we started Phase III for asthma, and we remember we have a breakthrough nomination for a FDA for atopic dermatitis. So those are a plans. we can’t envision accurately when a Phase IIIs will finish, though that within a timeline that we requested.
Sébastien Martel
Thank you, Elias. We’re going to take a integrate of some-more questions. So we’ve extended a call a small bit over what we said, given a energy mangle we had. So, we will take dual some-more and afterwards undo a call. Next please.
Operator
Thank you. The subsequent doubt is from Alexandra Hauber of UBS. Please go ahead.
Alexandra Hauber
Thank we for holding my question. we have a doubt for David first. Given that a lot of a Lemtrada income occurred upfront, can we greatfully maybe give us some thought about a further of patients, what we see? Are they adding during a regular, matching weekly studious adds, or are they accelerating or was there a reward upfront?
And afterwards secondly, Peter, sorry, if we come behind again to a pricing doubt in diabetes. So to promulgate all that I’ve listened so distant is, on a one side, you’re observant a 15% cost outcome will stay a same for Lantus by all this year, nonetheless there has been a excellence in a constrictive devise that was compulsory to change a guidance.
I therefore interpretation that that excellence is associated to Toujeo and therefore means larger discounts in a year than we had formerly anticipated. Is that finish correct, or am we blank something? Thank we unequivocally much.
Olivier Brandicourt
All right. And appreciate we Alexandra. David, Lemtrada?
David Meeker
Yeah. There was no bolus upfront and we consider a approach we consider about this is there is some certain mechanics and they go with Lemtrada launch, sound privately a REMS programs. So a initial 3 months of launch of a post-approval duration was intensively focused on removing medical providers on physicians, pharmacies, et cetera lerned and approved in a REMS. So we done extensive swell there.
The full sales force was on house as of a commencement of a February. So we’re fundamentally into a third month of former launch in that clarity and what we’re saying is a solid ramp in a series of patients who are signing adult for a program. In other words, a patients themselves have to enter a REMS module and that’s one of a pointer there so. So we would — there’s been — there is no bolus of investigate ramp on a initial launch.
Sébastien Martel
Thank you, David. Peter?
Peter Guenter
Yeah, Alexandra. So I’ll make a try to answer as good as we could and any additional granular information would be giving divided commercially supportive information. So appreciate we for your understanding.
Alexandra Hauber
Thank you.
Sébastien Martel
We’re going to take one final question, Operator.
Operator
Thank you. The final doubt is from Philippe Lanone of Natixis. Please go ahead.
Philippe Lanone
Hello, gentlemen. Thank we for holding my question. A integrate if we may. One for Olivier on Praluent, given obviously, we come from a association primarily that has been a cholesterol leader. How can we see — can we give us some-more tone on how we see a intensity of that drug and how Sanofi is good prepared to launch it, gripping in mind that a tide accord is $1.8 billion? What are your ambitions on Praluent today? And second question, on a biosimilar insulin lispro, that is in Phase III, can we give us some calendar here for rising and how we will position that contra your other dual short-acting insulins, Afrezza and Apidra?
Olivier Brandicourt
Okay. Praluent, usually to give we what we did and afterwards let me answer your question. So we spent a sincerely good volume of time, indeed with a tellurian and U.S. team, to usually consider a preparedness for a launch. And we consider we are enlightening few things though we are good on a approach to be indeed unequivocally prepared for a launch.
So we feel that is your question, we feel flattering good that we’re going to puts onto market, of course, a unequivocally absolute medicine. But we’ll have prepared for — we’ll be prepared for a unequivocally successful launch. So what is a second doubt is for we Elias.
Elias Zerhouni
Yeah. The doubt is usually true brazen doubt about lispro. As we know a devise has been to be a finish solutions provider for diabetic patients. And as we know, [indiscernible] was a partial of that scenario. So as partial of a strategy, we consider shopping matching generally in opposite markets are going to be vicious to yield that full spectrum if we will. And so that’s partial of a strategy.
Philippe Lanone
Good. Thank you.
Sébastien Martel
Okay. Thank you, Elias. Olivier, we are now prepared to tighten a call. Well, interjection unequivocally most to all participants for your seductiveness now in Sanofi. And we demeanour brazen to speak to we unequivocally soon. Thank we everyone.
Operator
Ladies and gentlemen, this concludes this discussion call. Thank we all for your participation. You competence now disconnect.
Article source
Related Posts:
Astellas Pharma’s (ALPMF) CEO Yoshihiko Hatanaka on Q3
Cable Fights to Feed ‘Binge’ TV Viewers
Stock-Options Trading Halted After Data Feed Problem
Hawaiian Holdings’ (HA) CEO Mark Dunkerley on Q4 2014…
Schneider Electric’s (SBGSF) CEO Emmanuel Babeau on Q1